An AQbD driven stability indicating HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in plasma.

The increasing prevalence of HIV has made us rely on a fixed dose combination (FDC) of anti-retroviral agents including lamivudine (LVD), tenofovir disoproxil fumarate (TDF) and efavirenz (EFZ) to ensure better therapeutic outcomes. In this context, the present study aims to develop and optimize Analytical Quality by Design (AQbD) employing D-optimal and Box-Behnken designs to simultaneously estimate LVD, TDF, and EFZ in a FDC. The optimized mobile phase (pH 4.